Adults with Cerebral Palsy Require Ongoing Neurologic Care
Ann Neurol 89:860-871, Smith, S.E.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis
Neruol 90:852-854, Ferraro, D.,et al, 2018
Malignancies after Mitoxantrone for Multiple Sclerosis
Neurol 86:2203-2207, Buttmann, M.,et al, 2016
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Enterovirus Vaccines for an Emerging Cause of Brain-Stem Encephalitis
NEJM 370:792-794, McMinn, P.C., 2014
ICU-Acquired Weakness and Recovery from Critical Illness
NEJM 370:1626-1635, Kress, J.P. & Hall, J.B., 2014
Herpes Simplex Virus Encephalitis:Clinical Manifestations,Diagnosis and Outcome in 106 Adult Patients
J Clin Virol 60:112-118, Sili,U.,et al, 2014
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Herpes Encephalitis During Natalizumab Tretament in Multiple Sclerosis
Mult Scler J 18:909-911, Kwiatkowski, A.,et al, 2012
Pediatric Neurological Complications of 2009 Pandemic Influenza A (H1N1)
Arch Neurol 68:455-462, Kedia, S.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Neonatal Cerebral Sinovenous Thrombosis From Symptom to Outcome
Stroke 41:1382-1388, Berfelo,F.J., et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Tick-Borne Encephalitis
Lancet 371:1861-1871, Lindquist,L. &Vapalahti,O., 2008
Percutaneous Clot Removal Devices in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Arch Neurol 65:1024-1030, Stead,L.G.,et al., 2008
Four New Cases of Therapy-Related Acute Promyelocytic Leukemia After Mitoxantrone
Neurol 71:457-458, Bosca,I.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Iatrogenic Cerebral Amyloid Angiopaty Post Neurosurgery:Frequency, Clinical Profile, Radiological Features, and Outcome
Stroke 54:1214-1223, 1224, Kaushik,K.,et al, 2023
Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Cerebral and Retinal Infarction in Bicuspid Aortic Valve
J Am Heart Assoc 12:e028789, Huntley,G.D.,et al, 2023
Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Clinicopathologic Conference, Plasm-Cell Myeloma Post-Transplant Lymphoproliferative Disorder
NEJM 386:2508-2516, Case 20-2022, 2022
A Brewing Back Pain
NEJM 385:66-72, Pischel, L.,et al, 2021
Clinicopathologic Conference, Fat Embolism Syndrome
NEJM 385:2464-2474, Case 39-2021, 2021
Multiple Brain Abscesses of Odontogenic Origin. May Oral Microbiota Affect Their Development? A review of the Current Literature
Appl Sci 11:3316, Montemurro,N.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection
JAMA Neurol 77:679-680, Pleasure, S.J.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Effects of Tranexamic Acid on Death, Disability, Vascular Occlusive Events and Other Morbidities in Patients with Acute Traumatic Brain Injury (CRASH-3): A Randomised, Placebo-Controlled Trial
Lancet 394:1713-1723,1687, The CRASH-3 trial collaborators, 2019
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Acute Brain Lesions on Magnetic Resonance Imaging and Delayed Neurological Sequelae in Carbon Monoxide Poisoning
JAMA Neurol 75:436-443, Jeon, S.B.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Clinical Presentation and Cranial MRI Findings of Listeria Monocytogenes Encephalitis
Neurologist 23:198-203, Arslan, F.,et al, 2018